Literature DB >> 10736116

Immunological cytokine correlates of protective immunity and pathogenesis in leprosy.

M C Lima1, G M Pereira, F D Rumjanek, H M Gomes, N Duppre, E P Sampaio, I M Alvim, J A Nery, E N Sarno, M C Pessolani.   

Abstract

The in vitro production of interferon (IFN)-gamma, interleukin (IL)-5, tumour necrosis factor (TNF)-alpha and IL-10 by blood mononuclear cells in response to whole Mycobacterium leprae and polyclonal stimulii of 23 individuals, representing a variety of conditions in relation to exposure/susceptibility to M. leprae, was assayed. In most cases, healthy household contacts of newly diagnosed multibacillary leprosy patients, designated exposed household contacts (EC), showed low-to-undetectable in vitro IFN-gamma production in addition to substantial TNF-alpha production in response to M. leprae. In contrast, peripheral blood mononuclear cells from previously exposed contacts (R) regarded as resistant-to-leprosy released low-to-moderate levels of IFN-gamma together with a mixed cytokine profile resembling a T helper (Th)0-type response. TNF-alpha/IL-10 ratios in response to M. leprae and Concanavalin A were significantly higher in EC than in R contacts suggesting a role for the TNF-alpha/IL-10 ratio in restraining mycobacteria proliferation and spreading early in infection. The cytokine profiles of leprosy patients were taken as reference points. Post-treatment lepromatous leprosy patients secreted relatively high levels of IL-10 in response to M. leprae, whereas one self-cured tuberculoid leprosy patient produced simultaneously high levels of IFN-gamma and TNF-alpha. In addition, the quantitative changes in the cytokines released by peripheral blood mononuclear cells in EC contacts after Bacille Calmette-Guérin (BCG) vaccination were investigated. Vaccination induced amplification of IFN-gamma production with a concomitant decrease in TNF-alpha/IL-10 ratios that resembled the cytokine pattern observed in R contacts. IFN-gamma production was observed in response to both a cross-reactive antigen (Ag 85) and a M. leprae-specific protein (MMP-I), which attests to a BCG nonspecific stimulation of the immune system, thereby casting these antigens as likely candidates for inclusion in a subunit vaccine against leprosy. Finally, a model for protective x pathologic response to mycobacteria is presented.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736116     DOI: 10.1046/j.1365-3083.2000.00703.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  17 in total

1.  IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy.

Authors:  Dheeraj Malhotra; Katayoon Darvishi; Soni Sood; Swarkar Sharma; Chander Grover; Vineet Relhan; B S N Reddy; R N K Bamezai
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

2.  Lateral flow assay for simultaneous detection of cellular- and humoral immune responses.

Authors:  Paul L A M Corstjens; Claudia J de Dood; Jolien J van der Ploeg-van Schip; Karien C Wiesmeijer; Terhi Riuttamäki; Krista E van Meijgaarden; John S Spencer; Hans J Tanke; Tom H M Ottenhoff; Annemieke Geluk
Journal:  Clin Biochem       Date:  2011-07-06       Impact factor: 3.281

3.  New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy.

Authors:  Annemieke Geluk; Kidist Bobosha; Jolien J van der Ploeg-van Schip; John S Spencer; Sayera Banu; Marcia V S B Martins; Sang-Nae Cho; Kees L M C Franken; Hee Jin Kim; Yonas Bekele; Mohammad K M Uddin; Sheikh Abdul Hadi; Abraham Aseffa; Maria C V Pessolani; Geraldo M B Pereira; Hazel M Dockrell; Tom H M Ottenhoff
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

Review 4.  Leprosy and the human genome.

Authors:  Elizabeth A Misch; William R Berrington; James C Vary; Thomas R Hawn
Journal:  Microbiol Mol Biol Rev       Date:  2010-12       Impact factor: 11.056

5.  Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Peter N Kazembe; Julie A Chatt; Elizabeth Norton; Hamish Dobbie; William R Jarvis
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Association of cytokine gene polymorphism with susceptibility and clinical types of leprosy.

Authors:  A Settin; S Nassar; A Abdel-Latif; R Elbaz; S El-Mongy; Aa Hassan; Am Hassan
Journal:  Int J Health Sci (Qassim)       Date:  2007-01

7.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

8.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.

Authors:  Luciana Silva Rodrigues; Mariana Andrea Hacker; Ximena Illarramendi; Maria Fernanda Miguens Castelar Pinheiro; José Augusto da Costa Nery; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani
Journal:  BMC Infect Dis       Date:  2011-12-13       Impact factor: 3.090

9.  Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.

Authors:  Nádia C Düppre; Luiz Antonio B Camacho; Anna M Sales; Ximena Illarramendi; José Augusto C Nery; Elizabeth P Sampaio; Euzenir N Sarno; Samira Bührer-Sékula
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

10.  Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue.

Authors:  Simeone Marino; Dhruv Sud; Hillarie Plessner; Philana Ling Lin; John Chan; JoAnne L Flynn; Denise E Kirschner
Journal:  PLoS Comput Biol       Date:  2007-08-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.